Pradaxa is an anticoagulant used to reduce the risk of stroke and prevent as well as treat the formation of blood clots (conditions such as deep vein thrombosis, pulmonary embolism, systemic thromboembolism, etc.) in patients suffering from atrial fibrillation as well as patients who have undergone a hip replacement surgery. This medicine is not recommended for use in patients less than 18 years of age.
Pradaxa from Boehringer contains Dabigatran. Dabigatran etexilate is prescribed for the prevention of thrombotic events in patients who underwent hip or knee replacement surgery. Dabigatran etexilate is used for the prevention of stroke in atrial fibrillation patients with other risks such as diabetes, hypertension, CHF, age and clinical history of stroke.
Pradaxa is product of Boehringer Ingelheim. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world’s largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company’s key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system.
A blood clot is a clump of blood that has changed from a liquid to a gel-like or semisolid state. Clotting is a necessary process that can prevent you from losing too much blood in certain instances, such as when you’re injured or cut.
When a clot forms inside one of your veins, it won’t always dissolve on its own. This can be a very dangerous and even life-threatening situation.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system.
An immobile blood clot generally won’t harm you, but there’s a chance that it could move and become dangerous. If a blood clot breaks free and travels through your veins to your heart and lungs, it can get stuck and prevent blood flow. This is a medical emergency.
As directed by physician
As directed by physician
Adverse Reactions/ Side Effects
The adverse events of Dabigatran are heavy menstrual periods, arthritis, weakness, bleeding tendency, discoloured urine, petechiae, malena, nausea, diarrhoea and food regurgitation with esophageal ulceration, mild skin rashes and fainting.
Warnings and Precautions
Dabigatran should be used with caution in elderly patients aged over 75 years and in patients with active peptic ulcer, bleeding and renal diseases.
Pregnancy USFDA pregnancy category C. May be or may not be harmful to an unborn baby. Consult your doctor if you are pregnant or planning to become pregnant during treatment.
Lactation- Nursing mothers should consult the healthcare provider before Ardeparin treatment.
Dabigatran and Geriatic- Elderly individuals are more prone to bleeding while using Dabigatran
Dabigatran may interact with warfarin, argatroban, clopidogrel, ticlopidine, abciximab, tirofiban, streptokinase, urokinase, quinidine, rifampicin, St. John’s wort, anti-arrhythmic drugs, calcium-channel blockers, NSAIDs and anti-fungal drugs.
Avoid alcoholic beverages while taking Dabigatran that may result in GI bleeding and/or perforation.